A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder

World Journal of Biological Psychiatry

Volumn 14, Issue 4, 2013, Pages 299-306

  Hammerness, Paul ^a   Zusman, Randall ^a   Systrom, David ^a   Surman, Craig ^a   Baggish, Aaron ^a   Schillinger, Mary ^a   Shelley Abrahamson, Rachel ^a   Wilens, Timothy E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ADHD; Cardiac; Cardiopulmonary; Lisdexamfetamine; Stimulant

Indexed keywords

ANTIHYPERTENSIVE AGENT; LISDEXAMFETAMINE;

ADULT; ANAEROBIC THRESHOLD; ANAMNESIS; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOPULMONARY EXERCISE TEST; CARDIOPULMONARY FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOCARDIOGRAPHY; DRUG DOSE TITRATION; DRUG SAFETY; DSM-IV; ELECTROCARDIOGRAM; EXTRASYSTOLE; FEMALE; GAS EXCHANGE; HEADACHE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE SIZE; HEART MUSCLE METABOLISM; HEART PERFORMANCE; HEART RATE; HEART RIGHT VENTRICLE CONTRACTION; HEART RIGHT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; INSOMNIA; MALE; MOOD CHANGE; OPEN STUDY; PSYCHOLOGIC ASSESSMENT; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEART; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84877603993     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2012.678884     Document Type: Article

References (34)

1. Adler LA, Weisler RH, Goodman DW, Hamdani M, Niebler GE. 2009. Short term effects of lisdexamphetamine dimesylate on cardiovascular parameters in a 4 week clinical trial in adults with ADHD. J Clin Psychiatr 70(12):1652-1661.
2. Adler L. 2009. Pharmacotherapy for adult ADHD. J Clin Psych 70(5):e12.
3. American Thoracic Society, American College of Chest Physicians. 2003. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Resp Crit Care Med 167(2):211-277.
4. Biederman J, Mick EO, Surman C, et al. 2007. Comparative acute effi cacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with ADHD. BMC Psychiatry 7:49.
5. Biederman J, Petty CR, Evans M, et al. 2010. How persistent is ADHD? A controlled 10 year follow up study of boys with ADHD. Psychiatry Res 177(3):299-304.
6. Bybee KA, Prasad A. 2008. Stress related cardiomyopathy syndromes. Circulation 118:397-409.
7. Castle L, Aubert RE, Verbrugge RR, et al. 2007. Trends in medication treatment for ADHD. J Attention Disord 10(4):335-342.
8. Cole CR, Foody JM, Blackstone EH, Lauer MS. 2000. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med 132(7):552-555. (Pubitemid 30171895)
9. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. 2011. ADHD Drugs and serious cardiovascular events in children and young adults. New Engl J Med. 365(20):1896-1904.
10. Fayyad J, De Graaf R, Kessler R, et al. 2007. Cross-national prevalence and correlates of adult attention-defi cit hyperactivity disorder. Br J Psychiatry 190:402-409. (Pubitemid 46706952)
11. FDA Safety Announcement Nov 1, 2011. FDA drug safety communication: Safety review update of medications used to treat ADHD in children and young adults (available at www.fda.gov/Drugs/DrugSafety/ucm277770.htm).
12. Gerhard T, Winterstein AG, Olfson M, et al. 2010. Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD. Pharmacoepidem Drug Saf 19(5):457-464.
13. Gibbins C, Weiss M. 2007. Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. Curr Psychiatry Rep 9(5):420-426. (Pubitemid 47565024)
14. Gorelik DD, Hadley D, Myers J, Froelicher V. 2006. Is there a better way to predict death using heart rate recovery? Clin Cardiol 29(9):399-404. (Pubitemid 44353327)
15. Habel L, Cooper W, Sox C, Chan A, Fireman R, Arbogast P, et al. 2011. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. J Am Med Assoc 306(24):2673-2683.
16. Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens, TE. 2011. Cardiovascular risk of stimulant treatment in pediatric attention defi cit hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatr 50(10): 978-990.
17. Kessler RC, Adler L, Barkley R, et al. 2006. The prevalence and correlates of adult ADHD in the United States: Results from the national comorbidity survey replication. Am J Psychiatry 163(4):716-723. (Pubitemid 44464584)
18. Lang RM, et al. 2005. Recommendations for Chamber Quantifi-cation: A report from the American Society of Echocardiography ' s Guidelines and Standards Committee and the Chamber Quantifi cation Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440-1463. (Pubitemid 41821197)
19. Lauer MS. 2009. Autonomic function and prognosis. Clev Clin J Med 76(Suppl 2):S18-22.
20. Mahon AD, Stephens BR, Cole AS. 2008. Exercise responses in boys with ADHD: effects of stimulant medication. J Attention Disord 12(2):170-176.
21. Makris N, Biederman J, Monuteaux MC, Seidman LJ. 2009. Towards conceptualizing a neural systems-based anatomy of ADHD. Dev Neurosci 31(1-2):36-49.
22. Mora S, Redberg RF, Cui Y, et al. 2003. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. J Am Med Assoc 290(12):1600-1607. (Pubitemid 37430384)
23. Movahed MR, Mostafi zi K. 2008. Reverse or inverted left ventricular apical ballooning syndrome in a young woman in the setting of amphetamine use. Echocardiography 25(4):429-432.
24. Nagueh SF, Appleton CP, Gillebert TC, et al. 2009. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10(2):165-193.
25. Perrin JM, Friedman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. 2008. Cardiovascular monitoring and stimulant drugs for attention-defi cit/hyperactivity disorder. Pediatrics 122(2):451-453.
26. Samuels JA, Franco K, Wan F, Sorof JM. 2006. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD. Pediatr Nephrol 21(1):92-95.
27. Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP et al. 2012. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psych Feb;169(2): 178-185.
28. Schubiner H, Hassunizadeh B, Kaczynski R. 2006. A controlled study of autonomic nervous system function in adults with ADHD treated with stimulant medications. J Attention Disord 10(2):205-211.
29. Spencer TJ, Adler LA, McGough JJ, et al. 2007. Effi cacy and safety of dexmethylphenidate extended-release capsules in adults with ADHD. Biol Psychiatry 61(12):1380-1387. (Pubitemid 46855767)
30. Spencer TJ. 2008. Neurobiology and genetics of ADHD in adults. CNS Spectrums Suppl 13:5-7.
31. Wilens T, Hammerness P, Biederman J, et al. 2005. Blood pressure changes associated with medication treatment of adults with ADHD. J Clin Psych 66(2):253-259. (Pubitemid 40314334)
32. Wilens T, Prince J, Spencer T, Biederman J. 2006. Stimulants and sudden death: what is a physician to do? Pediatrics 118(3):1215-1219. (Pubitemid 46090066)
33. Wilens TE, Zusman RM, Hammerness PG, et al. 2006. An openlabel study of the tolerability of mixed amphetamine salts in adults with ADHD and treated primary essential hypertension. J Clin Psychiatr 67(5):696-702. (Pubitemid 43946175)
34. Winterstein AG, Gerhard T, Shuster J, et al. 2007. Cardiac safety of central nervous system stimulants in children and adolescents with ADHD. Pediatrics 120(6):e1494-1501. (Pubitemid 350223669)